These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. A gene therapy strategy using a transcription factor decoy of the E2F binding site inhibits smooth muscle proliferation in vivo. Morishita R; Gibbons GH; Horiuchi M; Ellison KE; Nakama M; Zhang L; Kaneda Y; Ogihara T; Dzau VJ Proc Natl Acad Sci U S A; 1995 Jun; 92(13):5855-9. PubMed ID: 7597041 [TBL] [Abstract][Full Text] [Related]
7. Long-term stabilization of vein graft wall architecture and prolonged resistance to experimental atherosclerosis after E2F decoy oligonucleotide gene therapy. Ehsan A; Mann MJ; Dell'Acqua G; Dzau VJ J Thorac Cardiovasc Surg; 2001 Apr; 121(4):714-22. PubMed ID: 11279413 [TBL] [Abstract][Full Text] [Related]
8. The role of p16 in the E2F-dependent thymidine kinase regulation. Hengstschläger M; Hengstschläger-Ottnad E; Pusch O; Wawra E Oncogene; 1996 Apr; 12(8):1635-43. PubMed ID: 8622883 [TBL] [Abstract][Full Text] [Related]
9. Molecular strategy using cis-element 'decoy' of E2F binding site inhibits neointimal formation in porcine balloon-injured coronary artery model. Nakamura T; Morishita R; Asai T; Tsuboniwa N; Aoki M; Sakonjo H; Yamasaki K; Hashiya N; Kaneda Y; Ogihara T Gene Ther; 2002 Apr; 9(8):488-94. PubMed ID: 11948373 [TBL] [Abstract][Full Text] [Related]
10. Inhibition of mesangial cell proliferation by E2F decoy oligodeoxynucleotide in vitro and in vivo. Maeshima Y; Kashihara N; Yasuda T; Sugiyama H; Sekikawa T; Okamoto K; Kanao K; Watanabe Y; Kanwar YS; Makino H J Clin Invest; 1998 Jun; 101(11):2589-97. PubMed ID: 9616230 [TBL] [Abstract][Full Text] [Related]
11. Proto-oncogenic properties of the DP family of proteins. Jooss K; Lam EW; Bybee A; Girling R; Müller R; La Thangue NB Oncogene; 1995 Apr; 10(8):1529-36. PubMed ID: 7731707 [TBL] [Abstract][Full Text] [Related]
12. Ex-vivo gene therapy of human vascular bypass grafts with E2F decoy: the PREVENT single-centre, randomised, controlled trial. Mann MJ; Whittemore AD; Donaldson MC; Belkin M; Conte MS; Polak JF; Orav EJ; Ehsan A; Dell'Acqua G; Dzau VJ Lancet; 1999 Oct; 354(9189):1493-8. PubMed ID: 10551494 [TBL] [Abstract][Full Text] [Related]
13. Cooperative interactions between RB and p53 regulate cell proliferation, cell senescence, and apoptosis in human vascular smooth muscle cells from atherosclerotic plaques. Bennett MR; Macdonald K; Chan SW; Boyle JJ; Weissberg PL Circ Res; 1998 Apr; 82(6):704-12. PubMed ID: 9546379 [TBL] [Abstract][Full Text] [Related]
14. Epstein-Barr virus EBNA-LP and transcription regulation properties of pRB, p107 and p53 in transfection assays. Inman GJ; Farrell PJ J Gen Virol; 1995 Sep; 76 ( Pt 9)():2141-9. PubMed ID: 7561751 [TBL] [Abstract][Full Text] [Related]
15. E2F binding is required but not sufficient for repression of B-myb transcription in quiescent fibroblasts. Bennett JD; Farlie PG; Watson RJ Oncogene; 1996 Sep; 13(5):1073-82. PubMed ID: 8806697 [TBL] [Abstract][Full Text] [Related]
16. CDF-1, a novel E2F-unrelated factor, interacts with cell cycle-regulated repressor elements in multiple promoters. Liu N; Lucibello FC; Körner K; Wolfraim LA; Zwicker J; Müller R Nucleic Acids Res; 1997 Dec; 25(24):4915-20. PubMed ID: 9396796 [TBL] [Abstract][Full Text] [Related]
17. Inhibitory effects of novel E2F decoy oligodeoxynucleotides on mesangial cell proliferation by coexpression of E2F/DP. Park KK; Deok Ahn J; Lee IK; Magae J; Heintz NH; Kwak JY; Lee YC; Cho YS; Kim HC; Chae YM; Ho Kim Y; Kim CH; Chang YC Biochem Biophys Res Commun; 2003 Sep; 308(4):689-97. PubMed ID: 12927774 [TBL] [Abstract][Full Text] [Related]
18. Regulation of E2F: a family of transcription factors involved in proliferation control. Black AR; Azizkhan-Clifford J Gene; 1999 Sep; 237(2):281-302. PubMed ID: 10521653 [TBL] [Abstract][Full Text] [Related]